FXR agonist 15 

FXR agonist 15 is a selective, potent and orally active farnesoid X receptor (FXR) agonist with EC₅₀ of 0.76 μM. FXR agonist 15 exhibits no obvious activation on other nuclear receptors including LXRα/β, PXR, PPARα/β/γ, THR-β, with EC₅₀ values all >10 μM. FXR agonist 15 can alleviate steatosis, lobular inflammation, hepatocyte ballooning and liver fibrosis. FXR agonist 15 can be used for the research of nonalcoholic steatohepatitis (NASH)^[1].

FXR agonist 15 (Compound 19) (20 mg/kg, i.g., per day for 4 weeks) alleviates NASH by reducing liver steatosis, inflammation, and fibrosis in WD + CCl₄ (HY-Y0298)-induced mice NASH models^[1].
FXR agonist 15 (500 mg/kg, p.o., once daily for 10 days) causes no mouse death or abnormal behavior, shows no significant abnormalities in serum liver and kidney function indices (AST, ALT, ALP, creatinine, urea) and blood lipid indices (TG, TC), exhibits no acute toxic damage to major organs, and has good safety in ICR mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

526.40

C₂₄H₂₂Cl₂FNO₅S

2991276-14-1

FC1=CC(C2=CC=C(N(S(=O)(C3=C(Cl)C=CC=C3Cl)=O)CC(C)C)C=C2)=CC=C1OCC(O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wang W, et al. Design, synthesis, and biological studies of novel sulfonamide derivatives as farnesoid X receptor agonists. Eur J Med Chem. 2023;258:115614.  [Content Brief]